<DOC>
	<DOCNO>NCT02377752</DOCNO>
	<brief_summary>This study consist 2 part ( Part A Part B ) . The main purpose Part A evaluate safety side effect olaratumab combination doxorubicin Japanese participant group rare cancer ( advanced solid tumor , especially advanced soft tissue sarcoma [ STS ] . ) The main purpose Part B evaluate much olaratumab get blood stream Japanese participant advance solid tumor long take body get rid .</brief_summary>
	<brief_title>A Study Olaratumab Japanese Participants With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Part A : Have histological cytological evidence diagnosis advance metastatic solid tumor , especially STS , amenable treatment surgery radiotherapy . Part B : Have histological cytological evidence diagnosis solid tumor advance metastatic . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . Have give write informed consent prior studyspecific procedure . Have adequate organ coagulation function Have Eastern Cooperative Oncology Group ( ECOG ) performance score ( PS ) less equal 1 . Have discontinue previous treatment cancer recover acute effect therapy . ( Part A ) Have prestudy echocardiogram actual leave ventricular ejection fraction great equal 50 % , within 21 day prior first dose study medication . All participant agree use reliable method birth control donate sperm study least 16 week follow last dose study drug . Female participant : woman childbearing potential due surgical sterilization confirm medical history , menopause . woman childbearing potential test negative pregnancy within 7 day first dose study drug base serum urine pregnancy test agree breast feed study 4 month follow last dose study drug ( ) Have estimate life expectancy equal 3 month judgment investigator . Have receive treatment within 21 day initial dose study drug investigational product nonapproved use drug device noncancer indication concurrently enrol type medical research judge scientifically medically compatible study . ( Part A ) Have receive prior treatment doxorubicin , daunorubicin , idarubicin , and/or anthracyclines anthracenediones ( Part A ) Have receive prior radiation therapy mediastinal/pericardial area . Have symptomatic central nervous system malignancy metastasis . Participants treated central nervous system ( CNS ) metastases eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 60 day . Have elective plan major surgery perform course study . Have uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure great class II New York Heart Association guideline , severe myocardial insufficiency , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Have unstable angina pectoris , angioplasty , cardiac stenting , myocardial infarction 6 month prior study entry . Have know allergy treatment component . Have history allergic reaction attribute compound chemical biologic composition similar olaratumab . Have know active fungal , bacterial , and/or know viral infection Have correct QT interval great 470 millisecond ( msec ) screen electrocardiogram ( ECG ) Have second primary malignancy , judgment investigator sponsor , may affect interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>